New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
60-Word AI Digest
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Key Takeaways
- New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
- The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
- Click full coverage link below for the complete official dispatch.
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Original Publisher Attribution
This summary was curated from Wired.